Page 419 - Read Online

Page 7 of 36 J Cancer Metastasis Treat 2019;5:31 I http://dx.doi.org/10.20517/2394-4722.2019.21

reducing the toxic side-effects of the ineffective regimen, and enabling patients to move to potentially more
beneficial downstream or alternative treatments.

Biography
Dr. Parissenti is a professor of biochemistry at Laurentian University and the Northern Ontario School
of Medicine in Sudbury, ON Canada. The RNA Disruption Assay was developed through Dr. Parissenti’s
collaborations with clinical researchers from the Canadian Cancer Trials Group and Rna Diagnostics, Inc.
More information on RNA disruption and RDA can be obtained at http://rnadiagnostics.com.

9. ULLB-0005, a novel protein for cancer treatment

Sudeep Kumar

Unichem Laboratories Ltd, Pilerne Industrial Estate, Goa 403511, India.

Recombinant protein derived from a natural fungal protein, which has high binding specificity toward
the carbohydrate antigen. The natural Amino acid sequence has been modified to make more stable and
soluble protein. Modified sequence has been cloned and express in E. coli. The protein was purified through
different column chromatography and was characterized as a single protein. Promising cytotoxicity was
observed in different cancer cell line, with a good safety profile in human PBMCs with ULLB-0005. The
efficacy of the Molecule as antitumor agent was assessed in respective xenograft immuno-compromised
mice models in vivo. As expected the molecule showed strong anti-cancer activity in immune-compromised
mice model in various cancers which was observed in the reduction of tumor volume. Mechanistic
study showed strong apoptotic signal by modulating phosphatidyl serine externalization, mitochondrial
membrane depolarization, cell cycle arrest, ultimately leading to death in cancer cells. Inhibition of
proliferation and migration was observed in human endothelial cells, suggesting potential antiangiogenic
effect. Single dose Pharmacokinetic study was performed for the molecule in BALB/C MICE with i.v., i.p.
and i.m. route.

To elaluate this novel protein as a combination with chemotherapy further studies was conducted and
found that the molecule showed good synergy in in vitro with approved chemotherapeutic agents for Breast
and Pancreatic cancer. The inhibition potential of novel protein was determined for CYP3A4, CYP2C9,
CYP2D6, CYP1A2 & CYP2C19 using Cytochrome P450 inhibitor screening kit. None of these enzyme get
inhibited in the presence of molecule.

Biography
Dr. Sudeep Kumar did his Post Doc in Biotech from Valencia, Spain. He has more than 20 years of
experience in Biopharma. He has worked from R&D to tech transfer and manufacturing of different
recombinant proteins from bacteria and mammalian cell culture. He is dealing with different regulatory
agencies for approval and faced WHO, USFDA and other regulatory audits. He also actively involved with
clinical research team for Preclinical and clinical trials of recombinant proteins and vaccine. He established
the VLP technology platform for different vaccine in India in collaboration with Novavax. At present his
major research area to develop new recombinant protein for different cancer.